Table 2.
Eligible Studies included in Data Extraction
| WHO high-burden country | Total Number of HRQOL studies | Cross-sectional Design | Longitudinal Design |
|---|---|---|---|
| China | 2 [29, 69] | 1 | 1 |
| India | 6 [10, 12, 19, 26, 33, 70] | 1 | 5 |
| Indonesia | 2 [17, 66] | 2 | |
| Nigeria | 2 [14, 46] | 2 | |
| Pakistan | 1 [55] | 1 | |
| Philippines | 1 [9] | 1 | |
| South Africa | 6 [22, 42, 43, 45, 59, 63] | 6 | |
| Uganda | 1 [11] | 1 | |
| Other countries | Total Number of HRQOL studies | Cross-sectional Design | Longitudinal Design |
| Canada | 3 [27, 30, 40] | 2 | 1 |
| Iraq | 1 [58] | 1 | |
| Malaysia | 4 [18, 47, 64, 67] | 3 | 1 |
| Taiwan | 1 [20] | 1 | |
| Thailand | 1 [21] | 1 | |
| UK | 1 [39] | 1 | |
| USA | 2 [31, 36] | 2 | |
| Western Iran | 1 [65] | 1 | |
| Yemen | 1 [23] | 1 |
Table 2: Representation of eligible studies included in the systematic review and listed according to their WHO high-burden country status